• If you are wondering whether CME Group at around US$273.54 is offering fair value or not, this article walks through the key numbers that can help you frame that question clearly.
• The stock is down 6.1% over the last week and 5.5% over the last month, while the year to date return sits at 1.4% and the one year return is down 1.7%, set against gains of 68.0% over three years and 54.4% over five years.
• Recent moves in CME Group's share price have kept attention on how investors are weighing long term prospects against shorter term swings. Market participants are reacting to ongoing developments in trading volumes, interest rate expectations, and broader risk sentiment across exchanges and financial infrastructure stocks. These factors can influence how much investors are willing to pay for CME Group's earnings and cash flows at any given time.
• CME Group currently has a valuation score of 2 out of 6, and the sections that follow compare different valuation approaches before closing with a broader framework that can help you think about the stock's value in a more complete way.

CME Group scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: CME Group Excess Returns Analysis

The Excess Returns model looks at how efficiently CME Group turns shareholder capital into profits, then compares those profits to the return investors require. The gap between the company’s return on equity and its cost of equity is treated as “excess” value that can justify a premium over book value.

For CME Group, book value is $73.57 per share and the stable earnings figure used in this model is $13.63 per share, based on weighted future Return on Equity estimates from 5 analysts. The average Return on Equity is 15.97%, while the cost of equity is $6.70 per share. That leaves an excess return of $6.93 per share, which is capitalised over time on a stable book value assumption of $85.34 per share, sourced from weighted future Book Value estimates from 3 analysts.

On this basis, the Excess Returns model points to an intrinsic value of about $246.24 per share. Against a current share price around $273.54, this implies the stock is roughly 11.1% above the model’s estimate of fair value.

Result: OVERVALUED

Our Excess Returns analysis suggests CME Group may be overvalued by 11.1%. Discover 46 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: CME Group Price vs Earnings

For profitable companies like CME Group, the P/E ratio is a straightforward way to see how much you are paying for each dollar of earnings. It links directly to the bottom line and is widely used across the Capital Markets sector, which makes comparisons easier for you as an investor.

What counts as a reasonable P/E depends on what the market expects for future earnings and how risky those earnings are perceived to be. Higher expected growth or lower perceived risk can justify a higher multiple, while slower growth or higher risk usually calls for a lower one.

CME Group currently trades at about 23.4x earnings. This sits below the Capital Markets industry average P/E of about 39.5x and below the peer average of around 26.7x. Simply Wall St's Fair Ratio for CME Group is 15.4x. This is a proprietary estimate of what the P/E could be given factors such as earnings growth, industry, profit margin, market cap and company specific risks.

Because the Fair Ratio adjusts for these factors, it offers a more tailored reference point than simple peer or industry comparisons. With CME Group's actual P/E of 23.4x above the Fair Ratio of 15.4x, the stock screens as pricing in a richer earnings multiple than this framework suggests.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your CME Group Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as your chance to attach a clear story to the numbers by setting your own assumptions for CME Group's future revenue, earnings and margins. You can link that story directly to a financial forecast and a Fair Value that you can compare with the current price, all within an easy tool on Simply Wall St's Community page that updates automatically when new information such as earnings or news arrives. One investor might build a Narrative around the higher analyst target of US$353.00 that reflects confidence in areas like international expansion and product breadth. Another might lean toward the lower target of US$230.00 because of concerns about competition, regulation or volume trends. Seeing those different Fair Values next to the live share price can help you decide whether the stock looks more attractive, less attractive, or close to fairly priced against your own view of the story.

Do you think there's more to the story for CME Group? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.